Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ertugliflozin in pediatric type 2 diabetes mellitus
NCT04029480Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2019
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 22
01
Overview
A Phase 3 trial of ertugliflozin in type 2 diabetes mellitus (T2DM), sponsored by Merck & Co.. Started Oct 2019; status: completed.
02
Drugs
ertugliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04029480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04029480.